Fortress Biotech, Inc. (FBIO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FBIO SEC filings page.
Fortress Biotech, Inc. (FBIO) reported $68.5M in revenue over the twelve months to Jun 30, 2026, up 15.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Fortress remains an operating-loss business whose reported profit is produced below operations, while financing reshapes its balance sheet.
Earnings quality is weak: FY2025 reported net income of$37M coexisted with an operating loss of$70.2M and operating cash flow of-$65.8M , so the headline profit does not represent cash generated by the core business. The gap matters because it indicates that results below operating income, rather than operating performance, drove reported profitability.
The business improved its gross margin from
Balance-sheet pressure eased: the current ratio rose from 1.3x to 2.5x and debt-to-equity fell from 2.5x to 1.1x, but FY2025 financing cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Fortress Biotech, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Fortress Biotech, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 22/100.
Fortress Biotech, Inc.'s revenue grew 9.7% year-over-year to $63.3M, a solid pace of expansion. This earns a growth score of 7/100.
Fortress Biotech, Inc. has a moderate D/E ratio of 1.09. This balance of debt and equity financing earns a leverage score of 45/100.
With a current ratio of 2.49, Fortress Biotech, Inc. holds $2.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Fortress Biotech, Inc. generates a 13.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 19/100. This is up from -202.3% the prior year.
Fortress Biotech, Inc. scores -5.65, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $734.1M against total assets of $185.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Fortress Biotech, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Fortress Biotech, Inc. used $9.65 of operating cash (-$65.8M OCF vs $6.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Fortress Biotech, Inc. reported an operating loss of $70.2M against $10.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Fortress Biotech, Inc. generated $18.7M in revenue in Q2 2026. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.
Fortress Biotech, Inc.'s EBITDA was -$8.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Fortress Biotech, Inc. reported a net loss of $468K in Q2 2026. This represents a decrease of 103.0% from the same quarter a year earlier. Against the prior quarter it is down 100.4%.
Cash & Balance Sheet
Fortress Biotech, Inc. held $196.6M in cash against $35.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Fortress Biotech, Inc.'s gross margin was 67.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.
Fortress Biotech, Inc.'s operating margin was -53.5% in Q2 2026, reflecting core business profitability. Against the prior quarter it is down 5.2 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Fortress Biotech, Inc.'s net profit margin was -2.5% in Q2 2026, showing the share of revenue converted to profit. This is down 96.9 percentage points from the same quarter a year earlier.
Fortress Biotech, Inc.'s quarterly ROE was -0.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 35.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 68.3 percentage points.
Capital Allocation
Fortress Biotech, Inc. invested $805K in research and development in Q2 2026. This represents a decrease of 90.1% from the same quarter a year earlier. Against the prior quarter it is up 49.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
FBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M+14.0% | $16.0M+22.1% | $16.1M+6.3% | $17.6M+20.5% | $16.4M+10.2% | $13.1M+0.8% | $15.1M-24.2% | $14.6M-57.9% |
| Cost of Revenue | $6.1M+24.4% | $6.2M+29.8% | $5.4M+16.3% | $5.8M+28.7% | $4.9M-13.8% | $4.8M-20.2% | $4.7M+108.1% | $4.5M-30.5% |
| Gross Profit | $12.6M+9.6% | $9.8M+17.6% | $10.6M+1.9% | $11.9M+16.9% | $11.5M+25.1% | $8.3M+18.8% | $10.4M-41.0% | $10.2M-64.1% |
| R&D Expenses | $805K-90.1% | $540K-86.3% | -$371K-96.2% | $208K-97.8% | $8.1M-35.9% | $3.9M-84.1% | $9.7M-31.3% | $9.4M-53.6% |
| SG&A Expenses | $20.8M-46.3% | $15.9M-38.1% | $14.6M-46.0% | $17.4M-20.8% | $38.8M+86.1% | $25.7M+43.0% | $27.0M+38.6% | $22.0M+1.2% |
| Operating Income | -$10.0Mn/m | -$7.7Mn/m | -$4.6Mn/m | -$6.8Mn/m | -$36.5Mn/m | -$22.3Mn/m | -$23.9Mn/m | -$22.1Mn/m |
| EBITDA | -$8.9Mn/m | -$6.5Mn/m | -$3.5Mn/m | -$5.6Mn/m | -$35.3Mn/m | -$21.1Mn/m | -$22.8Mn/m | -$21.2Mn/m |
| Interest Expense | $1.5M-41.4% | $3.4M+20.1% | $2.0M-21.3% | $2.7M-55.8% | $2.5M+18.7% | $2.8M+7.8% | $2.6M+25.9% | $6.2M+145.0% |
| Income Tax | $320Kn/m | $5.1Mn/m | -$646K-365.8% | $26K-62.3% | $0n/m | $0n/m | $243K-36.1% | $69K-51.1% |
| Net Income | -$468K-103.0% | $110.4Mn/m | -$3.9Mn/m | $5.8Mn/m | $15.5Mn/m | -$10.6Mn/m | -$6.8Mn/m | -$12.9Mn/m |
| EPS (Basic) | -$0.08 | $3.44 | -$0.23n/m | $0.13 | $0.50 | -$0.48n/m | -$0.26 | -$0.76 |
| EPS (Diluted) | -$0.08 | $2.82 | -$0.21n/m | $0.11 | $0.45 | -$0.48n/m | -$0.26 | -$0.76 |
| Diluted Shares (Avg) | 32M | 38M | N/A | 33M | 30M | 26M+54.2% | N/A | 20M |
FBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $316.7M+98.1% | $356.9M+100.4% | $185.5M+28.7% | $181.4M+42.7% | $159.9M+9.8% | $178.1M+8.2% | $144.2M-13.9% | $127.1M-15.6% |
| Current Assets | $245.5M+122.4% | $295.5M+132.8% | $123.8M+37.0% | $118.5M+37.4% | $110.4M+6.7% | $126.9M+8.9% | $90.4M-22.8% | $86.3M-11.8% |
| Cash & Equivalents | $196.6M+164.3% | $255.8M+180.1% | $79.4M+38.6% | $86.2M+46.5% | $74.4M-2.4% | $91.3M+9.0% | $57.3M-29.2% | $58.9M-18.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $8.2M-36.5% | $9.3M-25.6% | $9.6M-33.3% | $11.8M+0.3% | $12.9M+32.7% | $12.5M+18.1% | $14.4M+41.4% | $11.8M+6.9% |
| Accounts Receivable | $36.2M+131.7% | $25.0M+38.7% | $29.8M+191.1% | $18.0M+68.5% | $15.6M+49.5% | $18.0M+83.9% | $10.2M-32.8% | $10.7M+33.6% |
| Long-Term Investments | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| Total Liabilities | $110.6M-9.7% | $154.5M+6.1% | $123.4M-15.4% | $116.2M+9.7% | $122.5M-23.6% | $145.6M-13.6% | $145.9M-12.1% | $105.9M-35.3% |
| Current Liabilities | $62.0M+7.8% | $103.4M+40.3% | $49.7M-30.3% | $54.1M-23.1% | $57.5M-23.9% | $73.7M-16.0% | $71.4M-15.9% | $70.3M-27.8% |
| Non-Current Liabilities | $48.6M-25.2% | $51.1M-28.9% | $73.6M-1.1% | $62.2M+74.5% | $65.0M-23.3% | $71.9M-11.1% | $74.5M-8.1% | $35.6M-46.4% |
| Long-Term Debt | $35.0M-30.0% | $37.5M-33.5% | $54.5M-6.0% | $47.8M-9.0% | $50.0M-25.3% | $56.4M-8.2% | $58.0M-4.8% | $52.5M+14.6% |
| Total Equity | $164.1M+273.7% | $162.2M+629.0% | $49.9M+119.3% | $55.9M+164.0% | $43.9M+145.7% | $22.3M-3.4% | $22.7M+0.9% | $21.2M+26.9% |
| Retained Earnings | -$624.1Mn/m | -$623.7Mn/m | -$734.1Mn/m | -$730.1Mn/m | -$736.0Mn/m | -$751.5Mn/m | -$740.9Mn/m | -$734.1Mn/m |
Not reported in any period shown, so not listed: Goodwill.
FBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$59.3Mn/m | $203.9Mn/m | -$12.5Mn/m | -$6.1Mn/m | -$27.6Mn/m | -$19.6Mn/m | -$12.9Mn/m | -$20.1Mn/m |
| Depreciation & Amortization | $1.1M-8.2% | $1.2M+2.4% | $1.2M+2.8% | $1.2M+27.4% | $1.2M-4.1% | $1.2M0.0% | $1.1M-5.6% | $914K-24.7% |
| Stock-Based Compensation | $2.9M-82.9% | $1.8M-72.1% | N/A | $3.2M-51.4% | $16.8M+236.0% | $6.3M+29.5% | N/A | $6.6M+50.2% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | -$1.4M+139400.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$12.9Mn/m | -$21.5Mn/m |
| Investing Cash Flow | -$79K-101.3% | $0-100.0% | $0n/m | $2.9Mn/m | $6.1Mn/m | $1.2Mn/m | -$15.0Mn/m | $0-100.0% |
| Financing Cash Flow | $91K-98.0% | -$27.4M-152.5% | $5.7M-77.9% | $15.1M+456.0% | $4.5M-68.3% | $52.1M+87.2% | $25.8M-40.8% | $2.7Mn/m |
| Dividends Paid | N/A | $0-100.0% | $166K0.0% | $166K-5.7% | $166K-5.7% | $166K-5.7% | $166K-7.8% | $176K-4.9% |
Not reported in any period shown, so not listed: Share Buybacks.
FBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.2%-2.7pp | 61.2%-2.3pp | 66.2%-2.9pp | 67.4%-2.1pp | 69.9%+8.4pp | 63.5%+9.6pp | 69.0%-19.7pp | 69.4%-12.1pp |
| Operating Margin | -53.5% | -48.3% | -28.7% | -38.6% | -222.2% | -169.8% | -158.3% | -151.0% |
| Net Margin | -2.5%-96.9pp | 688.2% | -24.5%+20.3pp | 33.2%+121.1pp | 94.3%+167.9pp | -80.5% | -44.7%+1.8pp | -88.0%-73.4pp |
| Return on Equity | -0.3%-35.6pp | 68.0%+115.6pp | -7.9%+21.9pp | 10.5%+71.3pp | 35.3%+96.5pp | -47.6%+19.4pp | -29.8%+11.4pp | -60.8%-30.6pp |
| Return on Assets | -0.1%-9.8pp | 30.9%+36.9pp | -2.1%+2.6pp | 3.2%+13.3pp | 9.7%+17.2pp | -5.9%+3.4pp | -4.7%+0.9pp | -10.1%-6.8pp |
| Current Ratio | 3.96+2.0x | 2.86+1.1x | 2.49+1.2x | 2.19+1.0x | 1.92+0.6x | 1.72+0.4x | 1.27-0.1x | 1.23+0.2x |
| Debt-to-Equity | 0.21-0.9x | 0.23-2.3x | 1.09-1.5x | 0.86-1.6x | 1.14-2.6x | 2.53-0.1x | 2.55-0.2x | 2.48-0.3x |
| Liabilities-to-Equity | 0.67-2.1x | 0.95-5.6x | 2.47-3.9x | 2.08-2.9x | 2.79-6.2x | 6.54-0.8x | 6.42-0.9x | 5.01-4.8x |
| Asset Turnover | 0.060.0x | 0.040.0x | 0.090.0x | 0.100.0x | 0.100.0x | 0.070.0x | 0.100.0x | 0.12-0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -85.4% | -146.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. FBIO | FY2025 | $63.3M | $6.8M | 10.8% | $64.4M | 28/100 |
| KALA BIO, Inc. KALA | FY2025 | $0 | -$27.0M | N/A | $3.6M | — |
| Corbus Pharmaceuticals Holdings, Inc. CRBP | FY2025 | N/A | -$78.5M | N/A | $79.9M | — |
| Adagene Inc. ADAG | FY2025 | $7.7M | -$17.6M | N/A | $163.8M | 64/100 |
| MacroGenics, Inc. MGNX | FY2025 | $149.5M | -$74.6M | -49.9% | $231.2M | 57/100 |
Where Fortress Biotech, Inc. Ranks
Frequently Asked Questions
What is Fortress Biotech, Inc.'s annual revenue?
Fortress Biotech, Inc. (FBIO) reported $63.3M in total revenue for fiscal year 2025. This represents a 9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Fortress Biotech, Inc.'s revenue growing?
Fortress Biotech, Inc. (FBIO) revenue grew by 9.7% year-over-year, from $57.7M to $63.3M in fiscal year 2025.
Is Fortress Biotech, Inc. profitable?
Yes, Fortress Biotech, Inc. (FBIO) reported a net income of $111.8M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $6.8M, with a net profit margin of 10.8%.
What is Fortress Biotech, Inc.'s EBITDA?
Fortress Biotech, Inc. (FBIO) had EBITDA of -$65.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Fortress Biotech, Inc. have?
As of fiscal year 2025, Fortress Biotech, Inc. (FBIO) had $79.4M in cash and equivalents against $54.5M in long-term debt.
What is Fortress Biotech, Inc.'s gross margin?
Fortress Biotech, Inc. (FBIO) had a gross margin of 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Fortress Biotech, Inc.'s net profit margin?
Fortress Biotech, Inc. (FBIO) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Fortress Biotech, Inc.'s return on equity (ROE)?
Fortress Biotech, Inc. (FBIO) has a return on equity of 13.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Fortress Biotech, Inc.'s operating cash flow?
Fortress Biotech, Inc. (FBIO) recorded an outflow of $65.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Fortress Biotech, Inc.'s total assets?
Fortress Biotech, Inc. (FBIO) had $185.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Fortress Biotech, Inc. spend on research and development?
Fortress Biotech, Inc. (FBIO) invested $11.9M in research and development during fiscal year 2025.
What is Fortress Biotech, Inc.'s current ratio?
Fortress Biotech, Inc. (FBIO) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.
What is Fortress Biotech, Inc.'s debt-to-equity ratio?
Fortress Biotech, Inc. (FBIO) had a debt-to-equity ratio of 1.09 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Fortress Biotech, Inc.'s liabilities-to-equity ratio?
Fortress Biotech, Inc. (FBIO) had a liabilities-to-equity ratio of 2.47 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Fortress Biotech, Inc.'s return on assets (ROA)?
Fortress Biotech, Inc. (FBIO) had a return on assets of 3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Fortress Biotech, Inc.'s P/E ratio?
Fortress Biotech, Inc. (FBIO) trades at 0.6x earnings, its market capitalization divided by $111.8M net income, trailing 12 months to June 30, 2026. The market capitalization is $64.4M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Fortress Biotech, Inc.'s price-to-sales ratio?
Fortress Biotech, Inc. (FBIO) trades at 0.9x sales, its market capitalization divided by $68.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $64.4M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Fortress Biotech, Inc.'s Altman Z-Score?
Fortress Biotech, Inc. (FBIO) has an Altman Z-Score of -5.65, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Fortress Biotech, Inc.'s Piotroski F-Score?
Fortress Biotech, Inc. (FBIO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Fortress Biotech, Inc.'s earnings high quality?
For every $1 of reported earnings, Fortress Biotech, Inc. (FBIO) used $9.65 of operating cash (-$65.8M OCF vs $6.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Fortress Biotech, Inc. cover its interest payments?
Fortress Biotech, Inc. (FBIO) reported an operating loss of $70.2M against $10.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Fortress Biotech, Inc.?
Fortress Biotech, Inc. (FBIO) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.